|
 |
| home > directory > Health Protection Agency |
|
|
 PHARMACEUTICAL INDUSTRY DIRECTORY |
Health Protection Agency |
 |
|
|
The Health Protection Agency is a national organisation
which is dedicated to protecting people’s health and reducing the impact of
infectious diseases, chemical, poisons and radiation hazards. Formed in 2003 by bringing together expertise
in various aspects of public health the Agency has three national Centres, a
network of regional laboratories and over 3000 staff.
The Agency
derives a significant proportion of its income from commercial activities which
include : microbiological, chemical and radiological testing, research and
development contracts, custom biopharmaceutical manufacture of biological
products, consultancy and training, as well as products including diagnostic
kits and therapeutic medicines. The Agency
has four culture collections supplying authenticated bacterial, fungal, viral
and cell cultures on a global basis.
Core business areas include research and development of
vaccines against infectious diseases, process development and GMP manufacture
of biologics derived from microbial fermentation - particularly those requiring
containment or focused on the bio-defence market. As well as a wide range of services including
biosafety, GLP immunoassay and vaccine testing, evaluation of diagnostic tests
and in-vivo studies.
The Centre at Porton
Down works to improve the UK's
emergency response capability by developing the infrastructure for surveillance
and early recognition of events. To improve preparedness we run training
courses and co-ordinate emergency exercises to provide testing of emergency
plans. We produce CBRN guidance for health professionals, as well as
bio-security advice to UK,
US and European governments and other agencies. |
|
|
|
|
|
 |
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Biomedical Systems Names New Managing Director For European Headquarters
St. Louis, MO - Biomedical Systems, a global provider of centralized diagnostic services for
clinical trials, announced that Geert Dewulf, MD has been named the Managing Director,
European Operations. Dr. Dewulf will assume the top post in the company's European
Headquarters in Brussels, Belgium from Rita Jacobs, who will be retiring from that post after
27 years with the organization. Dr. Dewulf came to Biomedical Systems from Agfa Healthcare
where he served as Managing Director for Germany, Austria and Switzerland.
More info >> |
|
 |
|
